X. P. Liu

发表

Self-Cleaning and Antireflective Films for All-Glass Evacuated Tube Solar Collectors

J. N. Wang, H. L. Yang, L. J. Jiang, 2015 .

A specific inhibitor of janus kinase-3 increases survival in a transgenic mouse model of amyotrophic lateral sclerosis.

X. P. Liu, F. Uckun, V. Trieu, 2000, Biochemical and biophysical research communications.

In vivo toxicity and pharmacokinetic features of the janus kinase 3 inhibitor WHI-P131 [4-(4'hydroxyphenyl)-amino-6,7- dimethoxyquinazoline.

X. P. Liu, F. Uckun, C. L. Chen, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

Treatment of allergic asthma by targeting janus kinase 3-dependent leukotriene synthesis in mast cells with 4-(3', 5'-dibromo-4'-hydroxyphenyl)amino-6,7-dimethoxyquinazoline (WHI-P97).

X. P. Liu, F. Uckun, M. Keenan, 2000, The Journal of pharmacology and experimental therapeutics.

The active state of the AT1 angiotensin receptor is generated by angiotensin II induction.

X. P. Liu, S. Karnik, A. Husain, 1996, Biochemistry.

Inhibition of human glioblastoma cell adhesion and invasion by 4-(4'-hydroxylphenyl)-amino-6,7-dimethoxyquinazoline (WHI-P131) and 4-(3'-bromo-4'-hydroxylphenyl)-amino-6,7-dimethoxyquinazoline (WHI-P154).

X. P. Liu, F. Uckun, R. Narla, 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

Structure-based design of specific inhibitors of Janus kinase 3 as apoptosis-inducing antileukemic agents.

X. P. Liu, F. Uckun, S. Ghosh, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

4-(3'-Bromo-4'hydroxylphenyl)-amino-6,7-dimethoxyquinazoline: a novel quinazoline derivative with potent cytotoxic activity against human glioblastoma cells.

X. P. Liu, F. Uckun, D. E. Myers, 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

Targeting Janus kinase 3 to attenuate the severity of acute graft-versus-host disease across the major histocompatibility barrier in mice.

X. P. Liu, F. Uckun, B. Waurzyniak, 2001, Blood.

Structure-based design of novel anticancer agents.

X. P. Liu, F. Uckun, A. Vassilev, 2001, Current cancer drug targets.

Treatment of atherosclerosis in apolipoprotein E-deficient mice with 4-(3-Bromobenzoyl)-6,7-dimethoxyquinazoline (WHI-P164), a potent inhibitor of triglyceride synthesis.

X. P. Liu, C. L. Chen, V. Trieu, 2000, Journal of cardiovascular pharmacology.

Tyrosine kinase inhibitors against EGF receptor-positive malignancies.

X. P. Liu, F. Uckun, Y. Zheng, 2001, Methods in molecular biology.

An inhibitor of Janus kinase 3:4-(4-hydroxyphenylamino)-6, 7-dimethoxyquinazolin-1-ium chloride methanol solvate.

X. P. Liu, F. Uckun, E. Sudbeck, 2000, Acta crystallographica. Section C, Crystal structure communications.

Rational design of potent and selective EGFR tyrosine kinase inhibitors as anticancer agents.

X. P. Liu, F. Uckun, S. Ghosh, 2001, Current cancer drug targets.

Structure-based design of potent inhibitors of EGF-receptor tyrosine kinase as anti-cancer agents.

X. P. Liu, F. Uckun, E. Sudbeck, 1999, Anti-cancer drug design.